Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Seeks More Information On Use of Fuzeon With Needle-Free Injector

This article was originally published in The Pink Sheet Daily

Executive Summary

Roche/Trimeris received an “approvable” letter from FDA for the HIV therapy Fuzeon administered with a needle-free Biojector device.

You may also be interested in...



Trimeris Shifts Focus Away From Fuzeon, Toward Pipeline Diversity

Restructuring plan, expected to wrap up by early 2007, will transfer some Fuzeon marketing responsibilities to Roche.

Trimeris Shifts Focus Away From Fuzeon, Toward Pipeline Diversity

Restructuring plan, expected to wrap up by early 2007, will transfer some Fuzeon marketing responsibilities to Roche.

Fuzeon Needle-Free Delivery System To Be Resubmitted To FDA In Second Half 2006

Growth for Roche/Trimeris' HIV fusion inhibitor is expected to be driven by the new system, which is currently "approvable" at FDA, and updated HHS treatment guidelines.

Related Content

Topics

UsernamePublicRestriction

Register

PS061307

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel